BAY-293

Also Known As:

(R)-6,7-dimethoxy-2-methyl-N-(1-(4-(2-((methylamino)methyl)phenyl)thiophen-2-yl)ethyl)quinazolin-4-amine; 6,7-dimethoxy-2-methyl-N-(1-(4-(2-((methylamino)methyl)phenyl)thiophen-2-yl)ethyl)quinazolin-4-amine; BAY293

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Thiophenes: 257
    - BAY-293: 3
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinazolines: 402
      - BAY-293: 3
Organic Chemicals: 133
- Sulfur Compounds: 278
  - Thiophenes: 257
    - BAY-293: 3

Experts

1.	Fei, Jia: 1 article (12/2021)
2.	Huang, Guiping: 1 article (12/2021)
3.	Li, Chuting: 1 article (12/2021)
4.	Li, Zhendong: 1 article (12/2021)
5.	Liu, Yanjun: 1 article (12/2021)
6.	Su, Rui: 1 article (12/2021)
7.	Yang, Juhua: 1 article (12/2021)
8.	Yin, Zhao: 1 article (12/2021)
9.	Zhang, Keda: 1 article (12/2021)
10.	Funovics, Martin: 1 article (12/2021)

Related Diseases

1.	Colonic Neoplasms (Colon Cancer) 12/01/2021 - "This study shows that BAY-293 combinations are active against NSCLC cells not further amenable to mutated EGFR-directed targeted therapy and results likewise hold relevance for pancreatic and colon cancer."
2.	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 12/17/2021 - "BAY-293, an inhibitor of SOS1/Ras, was found to depress proliferation and colony formation in chronic myeloid leukemia cells with resistance and BCR-ABL independence. "
3.	Pancreatic Neoplasms (Pancreatic Cancer) 09/01/2022 - "Cytotoxicity of combinations of the pan-KRAS SOS1 inhibitor BAY-293 against pancreatic cancer cell lines."
4.	Neoplasms (Cancer) 09/01/2022 - "In conclusion, BAY-293 exhibits synergy with drugs in dependence of the tumor type and specific KRAS mutation."
5.	Lung Neoplasms (Lung Cancer) 12/01/2021 - "Cytotoxicity of combinations of the pan-KRAS inhibitor BAY-293 against primary non-small lung cancer cells."

Related Therapies and Procedures

1.	Therapeutics